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In 1906, Alois Alzheimer first documented the case of
Auguste Deter, a patient with a combination of cogni-
tive deficits, psychiatric symptoms, and microscopic brain
lesions. This histopathological and clinical constellation was
then designated by Emil Kraepelin as Alzheimer’s disease
(AD) [1]. Nowadays, AD became the most common pro-
gressive neurodegenerative disease and the most common
form of dementia among the elderly [2, 3]. In the clinic,
the late-onset AD (LOAD) accounts for 95% of all AD cases
and is currently considered as a genetic complex disorder
that is probably caused by a combination of multiple risk
alleles and environmental factors [4]. To date, APOE is the
only unequivocally established susceptibility gene for LOAD
[5]. However, it has been estimated that the variations of
APOE account for less than 50% of LOAD risk, suggesting
that there are additional genetic risk factors which remain to
be uncovered. Recent advances in genetic approaches led to
the identification of numerous risk genes for AD, which has
greatly extended our knowledge on the genetic components
of this disease [6]. In this special issue, the paper entitled
“Clinical Genetics of Alzheimer’s Disease” by Z. Zou et al.
outlined these novel susceptibility genes, such as CLU, CR1,
CD33, PICALM, BIN1, TREM2, and PLD3. More importantly,
they summarized the recent evidence regarding the functions
of these genes as well as their association with phenotypes
and pathogenesis of AD. This allowed readers to get a good
understanding on the research advances in the genetic basis
and pathological mechanisms of this devastating disease.
Regarding the neuropathology, AD is mainly charac-
terized by the formation of extracellular neuritic plaques
containing the amyloid-𝛽 peptide (A𝛽) and intraneuronal
accumulation of neurofibrillary tangles constituted by hyper-
phosphorylated tau protein. In 2002, John Hardy proposed
“amyloid hypothesis,” which emphasized A𝛽 accumulation
as the initial pathological events in the progression of AD
[7]. Therefore, therapeutic strategies against A𝛽, especially
A𝛽-induced neurotoxicity, have attracted a lot of attention
in recent years. In the current issue, by employing primary
neuron culture, C.-F. Lau et al. provided the first evidence
that testosterone could protect against A𝛽-induced synap-
tic dysfunction and degeneration in “Protective Effects of
Testosterone on Presynaptic Terminals against Oligomeric
𝛽-Amyloid Peptide in Primary Culture of Hippocampal
Neurons.”These exciting findings emphasized testosterone as
a potential endogenous target of drug development, which
might open up a new avenue for the prevention and treatment
of AD. Additionally, in this issue, another original paper enti-
tled “Inhibitory Effects of Edaravone in 𝛽-Amyloid-Induced
Neurotoxicity in Rats” by F. He et al. provided preclinical
evidence concerning the beneficial effects of edaravone, a
free radical scavenger mainly used for stoke treatment, in an
AD model induced by A𝛽 injection. For the first time, they
showed that edaravone could attenuate A𝛽-induced increase
of voltage-gated calcium channel currents and cholinergic
neurons losses, which subsequently improved learning and
memory performance. Their interesting finding implied that
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edaravone might have a practical clinical use for AD pre-
vention and treatment, emphasizing the notion that many
therapeutic agents possessed pleiotropic actions in addition
to their main applications.
In addition to its own neurotoxicity, A𝛽 as the central
pathological factor also initiates a series of secondary events
in AD progression, such as neuroinflammation. Activation
of microglia, the main immune cell in the brain, is consid-
ered as a central event in A𝛽-induced neuroinflammation.
Actually, several lines of evidence suggested a “double-edged
sword” function of microglia during the progression of
AD [8]. On one hand, long-term A𝛽 stimulation results
in the dysfunction of microglia in the brain, which is
characterized by the overproduction of proinflammatory
cytokines, subsequently leading to the bystander neuronal
and synaptic damage. On the other hand, activated microglia
participates in the phagocytosis of A𝛽 through its phagocytic
activity and thus prevents the deposition of A𝛽 and the
formation of amyloid plaques. In this special issue, a review
article entitled “Microglia in Alzheimer’s Disease” by Y. Li
et al. summarized the recent advances concerning microglia
during AD progression. Meanwhile, they also introduced
the recent basic and clinic efforts regarding how to prevent
and treat this disease via precise modulation of microglial
functions. Their contributions will greatly help the readers
to get a better understanding on the role of microglia and
neuroinflammation in the mechanisms and therapeutics of
AD.
In summary, the articles in this issue cover the recent
progress in the genetic basis and molecular mechanisms
underlying AD pathogenesis, accompanied with the devel-
opment of diagnostic approaches and therapeutic strategies
for this disease. We hope that the reader will extend their
knowledge about the basic and clinical aspects of AD through
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